152 related articles for article (PubMed ID: 16077923)
1. Characterization of cell lines derived from tumors induced by TC-1 cells in mice preimmunized against HPV16 E7 oncoprotein.
Smahel M; Smahelová J; Tejklová P; Tachezy R; Marinov I
Int J Oncol; 2005 Sep; 27(3):731-42. PubMed ID: 16077923
[TBL] [Abstract][Full Text] [Related]
2. Combined immunization with fusion genes of mutated E7 gene of human papillomavirus type 16 did not enhance antitumor effect.
Pokorná D; Macková J; Dusková M; Rittich S; Ludvíková V; Smahel M
J Gene Med; 2005 Jun; 7(6):696-707. PubMed ID: 15712328
[TBL] [Abstract][Full Text] [Related]
3. Analysis of tumor progression by transcriptional profiling of mouse MK16 cell lines transformed with human papillomavirus type 16 E6 and E7 oncogenes and activated H-ras.
Smahel M; Smahelová J; Tejklová P; Tachezy R; Jelínek F
Oncol Rep; 2005 Dec; 14(6):1665-74. PubMed ID: 16273273
[TBL] [Abstract][Full Text] [Related]
4. Modified HPV16 E7 Genes as DNA Vaccine against E7-Containing Oncogenic Cells.
Smahel M; Síma P; Ludvíková V; Vonka V
Virology; 2001 Mar; 281(2):231-8. PubMed ID: 11277695
[TBL] [Abstract][Full Text] [Related]
5. Exploiting the plant secretory pathway to improve the anticancer activity of a plant-derived HPV16 E7 vaccine.
Franconi R; Massa S; Illiano E; Mullar A; Cirilli A; Accardi L; Di Bonito P; Giorgi C; Venuti A
Int J Immunopathol Pharmacol; 2006; 19(1):187-97. PubMed ID: 16569357
[TBL] [Abstract][Full Text] [Related]
6. A DNA vaccine constructed with human papillomavirus type 16 (HPV16) E7 and E6 genes induced specific immune responses.
Yan Q; Cheung YK; Cheng SC; Wang XH; Shi M; Hu MH; Yong X
Gynecol Oncol; 2007 Jan; 104(1):199-206. PubMed ID: 17049969
[TBL] [Abstract][Full Text] [Related]
7. Modified HPV16 E7/HSP70 DNA vaccine with high safety and enhanced cellular immunity represses murine lung metastatic tumors with downregulated expression of MHC class I molecules.
Li H; Ou X; Xiong J
Gynecol Oncol; 2007 Mar; 104(3):564-71. PubMed ID: 17081598
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of immunogenicity of HPV16 E7 oncogene by fusion with E. coli beta-glucuronidase.
Smahel M; Pokorná D; Macková J; Vlasák J
J Gene Med; 2004 Oct; 6(10):1092-101. PubMed ID: 15386741
[TBL] [Abstract][Full Text] [Related]
9. Live cell vaccines expressing B7.1, monocyte chemoattractant protein 1 and granulocyte-macrophage colony stimulation factor derived from mouse HPV16-transformed cells.
Lakatosová-Andelová M; Jinoch P; Dusková M; Marinov I; Vonka V
Int J Oncol; 2008 Jan; 32(1):265-71. PubMed ID: 18097567
[TBL] [Abstract][Full Text] [Related]
10. Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection.
Cheung YK; Cheng SC; Sin FW; Xie Y
Vaccine; 2004 Dec; 23(5):629-38. PubMed ID: 15542183
[TBL] [Abstract][Full Text] [Related]
11. Combination of intratumoral injections of vaccinia virus MVA expressing GM-CSF and immunization with DNA vaccine prolongs the survival of mice bearing HPV16 induced tumors with downregulated expression of MHC class I molecules.
Nemeckova S; Smahel M; Hainz P; Mackova J; Zurkova K; Gabriel P; Indrova M; Kutinova L
Neoplasma; 2007; 54(4):326-33. PubMed ID: 17822323
[TBL] [Abstract][Full Text] [Related]
12. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens.
Huang CY; Chen CA; Lee CN; Chang MC; Su YN; Lin YC; Hsieh CY; Cheng WF
Gynecol Oncol; 2007 Dec; 107(3):404-12. PubMed ID: 17905417
[TBL] [Abstract][Full Text] [Related]
13. Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules.
Smahel M; Síma P; Ludvíková V; Marinov I; Pokorná D; Vonka V
Vaccine; 2003 Mar; 21(11-12):1125-36. PubMed ID: 12559790
[TBL] [Abstract][Full Text] [Related]
14. Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.
Mikysková R; Bubeník J; Vonka V; Smahel M; Indrova M; Bieblová J; Símová J; Jandlová T
Int J Oncol; 2005 Feb; 26(2):521-7. PubMed ID: 15645139
[TBL] [Abstract][Full Text] [Related]
15. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells.
Rampias T; Sasaki C; Weinberger P; Psyrri A
J Natl Cancer Inst; 2009 Mar; 101(6):412-23. PubMed ID: 19276448
[TBL] [Abstract][Full Text] [Related]
16. [Expression of the human papillomavirus type 16L/E7 fusion protein in E. coli and observation of its immunogenicity in mice].
Tian HW; Ye ZM; Lu ZH; Jao R; Bian T; Zhao L; Ruan L
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):33-7. PubMed ID: 16816859
[TBL] [Abstract][Full Text] [Related]
17. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein.
Préville X; Ladant D; Timmerman B; Leclerc C
Cancer Res; 2005 Jan; 65(2):641-9. PubMed ID: 15695409
[TBL] [Abstract][Full Text] [Related]
18. DNA vaccines against HPV-16 E7-expressing tumour cells.
De Marco F; Hallez S; Brulet JM; Gesché F; Marzano P; Flamini S; Marcante ML; Venuti A
Anticancer Res; 2003; 23(2B):1449-54. PubMed ID: 12820408
[TBL] [Abstract][Full Text] [Related]
19. DNA vaccines based on chimeric potyvirus-like particles carrying HPV16 E7 peptide (aa 44-60).
Pokorna D; Cerovska N; Smahel M; Moravec T; Ludvikova V; Mackova J; Synkova H; Duskova M; Hozak P; Veleminsky J
Oncol Rep; 2005 Oct; 14(4):1045-53. PubMed ID: 16142370
[TBL] [Abstract][Full Text] [Related]
20. Comparison of DNA- and mRNA-transfected mouse dendritic cells as potential vaccines against the human papillomavirus type 16 associated oncoprotein E7.
Dell K; Klein C; Gissmann L
Antivir Ther; 2008; 13(4):495-509. PubMed ID: 18672528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
